Why Arcus Biosciences, Inc.’s (RCUS) Stock Is Down 8.54%
As of Thursday, November 05, Arcus Biosciences, Inc.’s RCUS share price has dipped by 8.54%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Tudor Pop
Rosalio Madrigal
Jenna Brashear
Tudor Pop
| Share Statistics | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,249.1 | $203.5 | 57% |
|
| Shares Out (Mil) | 127.4 | 55.2 | 66% |
|
| Institutional Ownership | 95.2% | 93.3% | 66% |
|
| Float (Mil) | 107.2 | 40.4 | 61% |
|
| Beta | 1.09 | 1.05 | 64% |
|
| Avg Daily Volume (000s) | 1,287 | 569 | 73% |
|
| Price Change (52-week) |
(22.8%) | 38.8% | 36% |
|
| Growth | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 25.9% | 13.6% | 87% |
|
| Net Income (5yr) | (23.5%) | (10.7%) | 17% |
|
| EPS (5yr) | (7.9%) | 15.4% | 23 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (20.6%) | (15.7%) | 32% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 9 | 10 | |
| Current EPS | ($0.856) | ($3.476) | ($3.092) | |
| Month Ago EPS | ($0.842) | ($3.516) | ($3.123) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.850) | ($3.526) | ($3.340) | |
| Year/Year Chg | (14.8%) | 5.7% | (14.3%) | |
| Financials | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $100 | $40 | 26% |
|
| Net Income (TTM) (Mil) | ($453) | ($44) | 3% |
|
| EPS (TTM) | ($3.643) | ($1.400) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($465) | ($35) | 2% |
|
| Net Cash Flow (TTM) (Mil) | ($87) | $-0 | 17% |
|
| Long-Term Debt (Q1) (Mil) | $227 | $4 | 51% |
|
| Enterprise Value (Q1) (Mil) | $2,094 | $142 | 50% |
|
| Valuation | RCUS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.56 | 1.96 | 85% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (373.0%) | 67.6% | 1% |
|
| Net Margin | (453.0%) | (50.8%) | 2% |
|
| ROA | (50.6%) | (47.0%) | 11% |
|
| ROE | (114.1%) | (51.8%) | 8% |
|
| Liabilities to Assets | 56.2% | 29.6% | 50% |
|
| F-Score | 0 | 3 | na |
|
Arcus Biosciences, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors